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Drug-Phospholipid Complex-loaded Matrix Film Formulation for the Enhanced 
Transdermal Delivery of Quercetin 
Abstract 
A novel quercetin-phospholipid-complex(QPLC)-loaded matrix film for improved transdermal delivery of 
quercetin was developed. The QPLC formulation, prepared using a solvent-evaporation method, was 
optimized using a central-composite design. The optimized QPLC formulation was characterized by 
particle size and zeta potential analysis, thermal analysis, Fourier transform infrared spectroscopy (FTIR), 
and proton nuclear magnetic resonance spectroscopy (1H-NMR). QPLC formulation was functionally 
evaluated for solubility and in vitro dissolution of quercetin. Matrix films of pure quercetin (Q-MF)or QPLC 
QPLC-MF) were prepared using a solvent casting method. The prepared Q-MF and QPLC-MF were 
characterized for weight uniformity, folding endurance, moisture content, and moisture uptake. The films 
were also functionally characterized for in vitro diffusion of quercetin through a dialysis membrane and ex 
vivo permeability of quercetin across rat skin. Finally, the anti-inflammatory activity of the films was 
evaluated on carrageenan-induced paw edema in Wistar albino rats. The experimental design identified 
the optimal formulation and process variables for the preparation of QPLC. The validation of the obtained 
model using these values confirmed the suitability and robustness of the model. The physical-chemical 
characterization of the prepared QPLC supported the formation of a stable complex. The solubility 
analysis of QPLC showed a 22-fold increase in quercetin aqueous solubility, compared to pure quercetin. 
The dissolution results exhibited a significantly higher rate and extent of quercetin dissolution from QPLC 
compared to that of pure quercetin. The permeability of quercetin from Q-MF and QPLC-MF across rat 
skin mirrored those obtained from the dissolution studies. Topical application of QPLC-MF exhibited a 
significant (p<0.05) inhibition of carrageenan-induced paw edema in rats compared to that of Q-MF. This 
study provides a promising combination approach, i.e., phospholipid-based complexation and 
transdermal film formulation for improved transdermal delivery of quercetin and similar 
pharmacologically active phytoconstituents. 
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Drug-phospholipid complex-loaded matrix film formulation for 
enhanced transdermal delivery of quercetin.
Darshan R. Telangea, Kuldeep D. Wavarea, Arun T. Patila, Milind J. Umekara, Sridhar Anandb, 
Vivek S. Daveb*
aSmt. Kishoritai Bhoyar College of Pharmacy, New Kamptee, Nagpur, Maharashtra, India
bSt. John Fisher College, Wegmans School of Pharmacy, Rochester, NY, USA
ABSTRACT
A novel quercetin-phospholipid-complex (QPLC)-loaded matrix film for improved transdermal delivery of quercetin was 
developed. The QPLC formulation, prepared using a solvent-evaporation method, was optimized using a central-composite 
design. The optimized QPLC formulation was characterized by particle size and zeta potential analysis, thermal analysis, 
Fourier transform infrared spectroscopy (FTIR), and proton nuclear magnetic resonance spectroscopy (1H-NMR). QPLC 
formulation was functionally evaluated for solubility and in vitro dissolution of quercetin. Matrix films of pure quercetin 
(Q-MF) or QPLC (QPLC-MF) were prepared using a solvent casting method. The prepared Q-MF and QPLC-MF 
were characterized for weight uniformity, folding endurance, moisture content, and moisture uptake. The films were also 
functionally characterized for in vitro diffusion of quercetin through a dialysis membrane and ex vivo permeability of quercetin 
across rat skin. Finally, the anti-inflammatory activity of the films was evaluated on carrageenan-induced paw edema in 
Wistar albino rats. The experimental design identified the optimal formulation and process variables for the preparation of 
QPLC. The validation of the obtained model using these values confirmed the suitability and robustness of the model. The 
physical-chemical characterization of the prepared QPLC supported the formation of a stable complex. The solubility analysis 
of QPLC showed a 22-fold increase in quercetin aqueous solubility, compared to pure quercetin. The dissolution results 
exhibited a significantly higher rate and extent of quercetin dissolution from QPLC compared to that of pure quercetin. The 
permeability of quercetin from Q-MF and QPLC-MF across rat skin mirrored those obtained from the dissolution studies. 
Topical application of QPLC-MF exhibited a significant (p<0.05) inhibition of carrageenan-induced paw edema in rats 
compared to that of Q-MF. This study provides a promising combination approach, i.e., phospholipid-based complexation 
and transdermal film formulation for improved transdermal delivery of quercetin and similar pharmacologically active 
phytoconstituents.
KEY WORDS: Quercetin, phospholipid, solubility, permeability, transdermal, excipients
INTRODUCTION
Quercetin is a lipophilic molecule that belongs to 
the class of plant derived flavonoids (1-4). Studies 
have reported quercetin to elicit a wide range of 
pharmacological activities including, anti-hypertensive, 
anti-inflammatory, anti-proliferative, anti-diabetic, 
anti-neural disorders, and importantly anti-oxidant 
activity attributed to quenching of free-radicals by 
quercetin (5-12). Despite promising pharmacological 
effects, quercetin displays low bioavailability owing to 
its poor solubility in water (~1-7 μg/mL), simulated 
gastric juice (~ 5.5 μg/mL), and simulated intestinal 
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juice (~29 μg/mL) (13). It is thus appropriately 
classified as a BCS Class II drug. Furthermore, the 
oral bioavailability of quercetin has been reported 
to be negatively influenced by extensive first-pass 
metabolism. The bioavailability of quercetin after oral 
administration was reported to be only about 1% in 
humans (14-16). Novel formulation strategies are thus 
needed to improve the bioavailability of quercetin.
Among the recently explored formulation strategies 
for improving quercetin bioavailability include 
nanotechnology based formulations, polymeric 
micelles, microspheres, and solid dispersions (4, 17-
20). Hatahet et. al. prepared nanocrystal-based dermal 
gel formulation with quercetin, and demonstrated 
enhanced solubility and dissolution of quercetin in these 
formulations (7). The protective effect of quercetin on 
hydrogen peroxide induced toxicity on epithelial cell 
lines was also demonstrated. Wang et. al. evaluated 
a solid non-aqueous self-double emulsifying drug 
delivery system for the topical application of quercetin 
(21). The study showed a significant improvement in 
the permeability and accumulation of quercetin in the 
skin. Zhang et. al. developed a combined novel drug 
delivery system for improving the bioavailability and 
prolonging the retention time of curcumin in the body 
(22). Cai et. al. prepared huperzine A-phospholipids 
complex-loaded biodegradable thermosensitive gel 
PLGA-PEG-PLGA polymer gel as implant system for 
controlled release of huperzine A (23). Transdermal 
delivery is a promising strategy to bypass the first-
metabolism associated with oral administration. While 
the approaches explored in the studies mentioned above 
overcome a specific barrier to improve bioavailability i.e. 
solubility or permeability enhancement, a systematic, 
design-optimized, formulation development approach, 
complemented with detailed evaluation, is still needed.
Previously, studies have shown drug-phospholipids 
complexation as a successful approach for enhancing 
the aqueous solubility, permeability, and in vivo 
bioavailability of pharmacoactive molecules (23-29). 
In the current study this approach was taken a step 
further. Using a two-step approach, a phospholipid-
based complex of quercetin was first prepared. This 
prepared complex was then formulated into polymeric 
matrix films. The quercetin phospholipid complex 
formulation (QPLC) was prepared and optimized 
using a central composite design. The design-optimized 
formulation was characterized by particle size and 
zeta potential analysis, thermal analysis, Fourier 
transform infrared spectroscopy (FTIR), proton 
nuclear magnetic resonance spectroscopy (1H-NMR), 
powder x-ray diffractometry (PXRD), and solubility 
analysis. The dissolution behavior of QPLC was also 
compared to pure quercetin. The QPLC was then 
formulated into hydroxypropyl methyl cellulose-based 
matrix films (QPLC-MF) using a solvent casting 
method. The prepared films were then evaluated 
for physical properties such as thickness, weight 
variation, moisture content, and moisture uptake. 
The films were functionally characterized for in vitro 
diffusion across a dialysis membrane and ex vivo 
permeation across rat skin. Finally, the QPLC-loaded 
film was pharmacologically evaluated for in vivo anti-
inflammatory activity.
Materials and methods
Materials
Quercetin dihydrate (>99% purity) was obtained 
from Sisco Research Laboratories Pvt. Ltd., Mumbai, 
India. Phospholipon® 90H was obtained from Lipoid, 
Ludwigshafen, Germany. Carrageenan was obtained 
from Sigma-Aldrich Corporation, St. Louis, MO. 
Chloroform, dibutyl phthalate, dimethyl sulfoxide 
(DMSO), ethanol, n-hexane, hydroxypropyl methyl 
cellulose (HPMC E15) and methanol were obtained 
from Loba Chemicals Pvt. Ltd., Mumbai, India. Other 
chemicals used in the study were of analytical grade.
The formulation of the quercetin-phospholipid 
complex (QPLC)
The quercetin-phospholipids complex (QPLC) was 
prepared by a solvent evaporation method reported 
previously (26). Briefly, quercetin and Phospholipon® 
90H were weighed individually in molar ratios 
of 1:0.55, 1:1.05, 1:1.78, 1:2.51 and 1:3.00 and 
transferred to a 100 mL reflux flask. To this mixture 
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20 mL absolute ethanol was added and mixed well. 
The temperature of the flask was controlled at 40.4, 
44.4, 50.1, 56.2, or 60.2°C using a water bath. The 
reflux reaction was allowed to continue for 1.0, 1.4, 
2.1, 2.6 or 3.0 hours. After the reaction was complete, 
the flask contents was evaporated until a ~ 2-3 mL 
residue remained. 10 mL of n-hexane was added to this 
residue, resulting in the precipitation of the formed 
QPLC. The resultant QPLC was filtered and dried at 
40°C for 12 hours using vacuum drying. Finally, the 
dried QPLC powder was placed in an amber (light-
protected) glass vial, flushed with nitrogen and stored 
at room temperature until further characterization.
Optimizing variables (central composite design)
In line with previously published reports, a central 
composite design (Design-Expert®, Version 10.0.4.0, 
Stat-Ease Inc., Minneapolis, Minnesota, USA) was used 
to minimize the number of experiments and achieve 
the maximum possible information about the prepared 
formulation. Based on previous experience with similar 
studies, three independent variables, i.e. quercetin: 
phospholipid ratio (X1, w/w), reaction temperature (X2, 
°C), and reaction time (X3, h) were selected. Each of 
these variables were studied at three levels, numerically 
designated as -1 (low), 0 (middle), and +1 (high). The 
extent of quercetin inclusion (% yield) was chosen 
as the dependent variable. The software-generated 
design recommended 20 different combinations of 
independent variables. Thus, 20 experimental trial 
formulations were prepared and evaluated for quercetin 
inclusion. Upon analysis of data, the design showed the 
results in the form of a statistical model/polynomial 
Equation 1 shown below. The equation describes the 
significance of the coefficients of magnitude, and the 
interaction and polynomial terms useful in selecting 
the optimal levels of independent variables.
Where, Y and b represents the quercetin inclusion and 
the estimated coefficient of the term, X respectively. X1, 
X2 and X3 represents the main effects of the independent 
variables individually. The combined terms, X1 X2, X2 
X3  and X1 X3  shows the interactions between the 
variables. The polynomial terms, X12, X22 , and 
indicates the non-linearity of the responses. The 
experimental design with coded levels and the real 
values of the independent variables are shown in 
Table 1. The results of the quercetin inclusion efficiency 
obtained from the design generated experimental trials 
are shown in Table 2.
Table 1 Coded levels and real values for independent variables
VARIABLES LEVELS
-1.73 -1 0 +1 +1.73
Independent Real values
Quercetin : phospholipids ratio 
(X1, w: w)
1: 0.55 1:1.05 1:1.78 1:2.51 1:3.00
Reaction temperature (X2, °C) 40.4 44.4 50.1 56.2 60.2
Reaction time (X3, h) 1.0 1.4 2.1 2.6 3.00
Dependent
Extent of complexation or Yield 
(Y, % w/w)
Table 2 Quercetin inclusion efficiency obtained from the design-
generated experimental trials.
EXPERIMENTAL 
TRIALS X1 X2 X3
QUERCETIN 
INCLUSION 
EFFICIENCY 
(%, w/w)
1 -1 +1 +1 65.23 ± 0.10
2 0 -1.73 0 97.57 ± 0.16
3 0 +1.73 0 72.25 ± 0.23
4 0 0 0 95.38 ± 0.11
5 -1.73 0 0 68.50 ± 0.04
6 0 0 0 94.92 ± 0.22
7 -1 -1 -1 72.10 ± 0.45
8 0 0 -1.73 96.48 ± 0.15
9 -1 +1 -1 56.38 ± 0.33
10 +1 -1 +1 94.33 ± 0.19
11 0 0 0 94.29 ± 0.21
12 +1 -1 -1 83.03 ± 0.18
13 0 0 0 95.38 ± 0.75
14 0 0 0 95.38 ± 0.75
15 +1 +1 +1 86.60 ± 0.05
16 0 0 0 95.38 ± 0.15
17 +1.73 0 0 87.40 ± 0.20
18 +1 +1 -1 88.39 ± 0.16
19 0 0 +1.73 90.80 ± 0.03
20 -1 -1 +1 87.48 ± 0.10
Y b b X b X b X b X b X
b X b X X b X X b
= + + + + + +
+ + +
0 1 1 2 2 3 3 11 1
2
22 2
2
33 3
2
12 1 2 23 2 3 13 1 3X X
Eq. 1
X23
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Estimation of the quercetin inclusion in the prepared 
complex
 
The extent of the quercetin inclusion in the prepared 
complex was determined by a slightly modified method 
to that described previously (26). Briefly, an accurately 
weighed amount of the prepared QPLC (containing 
~  50 mg quercetin) was dispersed into 5 mL chloroform. 
The QPLC and any unused Phospholipon® 90H were 
readily dissolved in the chloroform. The unused (pure, 
non-complexed quercetin) remained undissolved, and 
was separated as a precipitate. This precipitate was 
separated by filtration (Whatman® quantitative filter 
paper, ashless, Grade 41, Sigma-Aldrich Corporation, 
St. Louis, MO), and dried at room temperature. The 
dried residue was dissolved in sufficient methanol, and 
after suitable dilutions, analyzed spectrally (Model: 
V-630, JASCO International Co., Ltd., Tokyo, Japan) 
at a wavelength of 381.2 nm. The amount of quercetin 
incorporated in the prepared QPLC was calculated 
using Equation 2.
Quercetin inclusion
C C
C
xt f
t
(%)=
−
100 Eq. 2
Where, Ct is the total theoretical amount of quercetin 
in QPLC used, and Cf is the amount of quercetin in 
the filtrate.
Preparation of the quercetin or QPLC-loaded matrix 
film formulation (Q-MF or QPLC-MF)
The quercetin or QPLC-loaded matrix films were 
prepared using a solvent casting method reported 
previously (30). Briefly, accurately weighed HPMC 
E15 (700 mg) was dispersed in a mixture of methanol: 
chloroform (1:1, 10 mL) using a magnetic stirrer 
until a homogeneous dispersion was formed. To this 
polymeric dispersion, dibutyl phthalate (plasticizer, 2 
mL) and dimethyl sulfoxide (permeation enhancer, 
0.5 mL) was added. The dispersion was stirred well to 
ensure the removal of air bubbles, if any. An accurately 
weighed amount of Q-MF (containing ~30 mg of 
quercetin) or QPLC (containing ~30 mg of quercetin, 
prepared earlier) was added to this dispersion stirring 
continuously to ensure that the quercetin or QPLC 
particles were uniformly distributed throughout 
the polymeric dispersion. This polymeric dispersion 
containing quercetin or QPLC was then poured 
into a pre-fabricated, circular glass well placed in 
a glass petri dish filled three fourths with mercury. 
The mold was covered with inverted glass funnel to 
qualitatively control the rate of solvent evaporation. 
The assembly was placed in a solvent hood overnight to 
facilitate solvent evaporation, and obtain dried films. 
The obtained dry matrix films were then packed in 
aluminum foil and stored in desiccators at a controlled 
temperature (25°C) until further use.
Physical-chemical characterization of QPLC
Particle size and zeta potential analysis
The particle size and zeta potential analysis of the 
design-optimized QPLC formulation was carried 
out using methods reported previously (28). Photon 
Cross Correlation Spectroscopy (PCCS) together 
with dynamic light scattering was used to evaluate the 
particle size distribution of the QPLC formulation. 
An aqueous dispersion (0.5 mg/mL) of QPLC was 
prepared and examined using a particle size analyzer 
(Model: NANOPHOX Sympatec, GmbH, Clausthal-
Zellerfeld, Germany). The equipment was sensitive 
in the range of 1 nm to 10 µm, and flexibility of 
positioning the sample to optimize the count rate 
using the associated software. A nano particle analyzer 
(NanoPlusTM-2, Particulate system, Norcross, GA, 
USA) equipped with dynamic light scattering was 
used to measure the zeta potential of the QPLC 
formulation. The measurements were conducted at 
room temperature within the equipment sensitivity 
range of -200 to 200 mV.
Thermal analysis
Differential scanning calorimetry (DSC) was used 
for comparative thermal characterization of the pure 
quercetin, Phospholipon® 90H, the physical mixture 
of quercetin and Phospholipon® 90H, and the design-
optimized QPLC formulation. The instrument 
(Model: DSC-1 821e, Mettler-Toledo AG, Analytical, 
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Schwerzenbach, Switzerland) was pre-calibrated for 
heat flow and heat capacity with high-purity indium 
standard. The sample chamber was continuously 
purged with nitrogen (50 mL/min). Individual samples 
(2.0 ± 0.2 mg) were subjected to a single heating cycle 
in the range of 40 to 400°C at the rate of 10°C/min. 
The DSC thermograms obtained for each sample were 
analyzed with the software (Universal Analysis 2000, 
V4.5A, build 4.5.0.5) accompanying the instrument.
Fourier transform infrared spectroscopy (FTIR)
Pure quercetin, Phospholipon® 90H, the physical 
mixture of quercetin and Phospholipon® 90H, and 
the design-optimized QPLC formulation were further 
chemically characterized and compared using an FTIR 
spectroscopy. The samples were tested using an FTIR 
spectrophotometer (Model: FTIR-8300, Shimadzu, 
Kyoto, Japan). Sample preparation involved preparing 
potassium bromide (KBr) pellets containing ~2 mg 
air-dried samples. Thin transparent discs of KBr were 
compressed on a Mini Hand Press (Model: MHP -1, 
P/N – 200-66747-91, Shimadzu, Kyoto, Japan) at a 
pressure of 10 ton/Nm2. Individual sample discs were 
scanned within a wavelength ranging from 4000 to 400 
cm-1, with a scan resolution of 4 cm-1. The obtained 
spectra were analyzed by the software (IRsolution 
FTIR control software, version 1.10) associated with 
the instrument.
Powder X-ray diffractometry (PXRD)
The comparative crystalline nature of pure quercetin, 
Phospholipon®  90H, the physical mixture of quercetin 
and Phospholipon® 90H, and the design-optimized 
QPLC formulation were studied using a PXRD on a 
x-ray diffractometer (Model: D8 ADVANCE, Bruker 
AXS, Inc., Madison, WI, USA) equipped with Bragg-
Brentano geometry (θ/2θ) optical setup. The method 
reported previously was used to analyze the samples 
(28).
Proton nuclear magnetic resonance spectroscopy 
(1H-NMR)
The structural framework of individual samples 
as well as the prepared QPLC formulation was 
analyzed by proton NMR using a 400 MHz FT-
NMR spectrophotometer (Model: Bruker Advance II, 
Bruker, Rheinstatten, Germany) with an operational 
temperature range of -90°C to 80°C.
Solubility analysis
The aqueous and non-aqueous solubility of pure 
quercetin, as well as quercetin in the physical mixture 
with Phospholipon® 90H, or in the prepared QPLC 
was determined using a procedure established 
previously (27). Briefly, 5 mL dispersions of samples 
were prepared in purified water or n-octanol and 
agitated on a water bath shaker (Model: RSB-12, Remi 
House, Mumbai, India) for 24 hours. The dispersions 
were then centrifuged at 1500 RPM for 25 minutes 
at ambient temperature (25°C). The dispersions, after 
centrifugation, were filtered using a membrane filter 
(0.45 µm). The filtrates, after appropriate dilution with 
water or methanol were assayed spectrally at 381.2 nm 
using UV-visible spectrophotometer (Model: V-630, 
JASCO International Co., Ltd., Tokyo, Japan).
Physical-chemical characterization of QPLC-MF
The physical-chemical attributes of the prepared 
QPLC-loaded matrix films were evaluated using 
various methods described below.
Film thickness and weight variation
The thickness of the prepared QPLC-loaded matrix 
films (surface area at 1.0 cm2) was measured using a 
digital thickness gauge (Model: 500-JD, Electromatic 
Equipment Co., INC. Cedarhurst, NY, USA). The 
measurements were carried out in triplicate and the 
mean calculated. The same films were used for weight 
variation study. The films were weighed using a digital 
balance (Model: CAS -164, serial no.1502677, capacity 
~160g, sensitivity ~0.1mg, Contech® Electronic 
Balance, Contech Instrument Pvt., Ltd., Mahape, 
Navi Mumbai) and calculating the average weight of 
six films. 
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Moisture content Final weight of film Initial weight of film
In
(%)= −
itial weight of film
x 100 Eq. 3
Folding endurance
The prepared films were evaluated for folding endurance 
using a well-established procedure (30). A 6 cm2 film 
is repeatedly folded at the same location multiple times 
until it breaks. The number of foldings required to 
break a film is described as the folding endurance. All 
measurements were carried out in triplicate.
Quercetin content in QPLC-MF
The quercetin content of the prepared QPLC-loaded 
matrix films was determined after extracting quercetin 
from a film sample of fixed dimensions (1 cm2). 
Briefly, the film was cut, weighed and transferred to 
a volumetric flask containing sufficient quantity of 
methanol. The flask contents were agitated on a water 
bath shaker (Model: RSB-12, Remi House, Mumbai, 
India) for 24 hours at 37°C. After 24 hours, the flask 
contents were filtered (Whatman® quantitative filter 
paper, ashless, Grade 41, Sigma-Aldrich Corporation, 
St. Louis, MO), the filtrate diluted suitably, and the 
solutions assayed spectrally at 381.2 nm on a UV-
visible spectrophotometer (Model: V-630, JASCO 
International Co., Ltd., Tokyo, Japan).
QPLC-MF moisture content
The moisture content of the prepared films was 
determined using the standard procedure reported 
earlier (30). Each sample formulation film (random 
triplicates of same dimensions) were individually 
weighed (initial weight) and placed in desiccators at a 
constant temperature (25°C). The films were weighed 
at regular intervals until a constant weight (final weight) 
for each film was achieved. The moisture content (%) 
was calculated using Equation 3.
QPLC-MF moisture uptake
The hygroscopicity (extent of ambient moisture 
uptake) of a film formulation is a good indicator of the 
physical stability of the films. To assess the moisture 
uptake of the prepared QPLC-loaded matrix films, 
the pre-weighed film samples of fixed dimensions were 
exposed to elevated humidity condition (saturated 
NaCl solution, ~75% RH). The samples were weighed 
at regular intervals until a constant weight was achieved 
(final weight). The moisture uptake (%) was calculated 
using Equation 3.
Functional characterization of QPLC and QPLC-MF
As described below, the prepared complex (QPLC) was 
first characterized for the in vitro release and diffusion of 
quercetin across a dialysis membrane. Subsequently, the 
prepared QPLC-loaded matrix film (QPLC-MF) was 
characterized for in vitro diffusion of quercetin across 
a dialysis membrane, ex vivo permeation efficiency of 
quercetin across rat abdominal skin membrane, and in 
vivo anti-inflammatory activity in rats.
In vitro dissolution studies
The dissolution profiles of pure quercetin and the 
prepared complex (QPLC) were compared using 
a dialysis method described earlier by Maiti et. 
al. (31). The dialysis membrane (LA395, dialysis 
membrane-110, average diameter ~21.55 mm, average 
flat width ~32.34 mm, capacity ~3.63 mL/cm; 
HiMedia Laboratories, Mumbai, India) was pre-treated 
and rinsed according to the manufacturer’s guidelines. 
The molecular size cut off of the dialysis membrane was 
12000 – 14000 Da. The dialysis bags were prepared and 
loaded with samples i.e., pure quercetin suspension in 
phosphate buffer saline (PBS, pH 7.4, containing ~5 
mg quercetin) or QPLC (containing ~5 mg quercetin). 
The sample loaded bags were vertically suspended in a 
beaker containing PBS (200 mL, pH 7.4) and Tween® 
20 (1% w/w) as a dissolution medium. The assembly 
was stirred at 50 RPM, and the temperature of the 
dissolution medium was maintained at 37.0 ± 2.0°C. 
At regular intervals, aliquots (5 mL) of the dissolution 
medium were removed, diluted suitably with PBS, and 
absorbance recorded at 381.2 nm (ƛmax for quercetin 
in PBS, pH 7.4) on a UV-visible spectrophotometer 
(Model: V-630, JASCO International Co., Ltd., 
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Tokyo, Japan).
In vitro diffusion studies
The in vitro diffusion of quercetin from the quercetin-
loaded matrix films (Q-MF) and QPLC-loaded matrix 
film (QPLC-MF) were determined using a method 
reported previously by Parhi et. al. (32). The studies 
were carried out using a Franz diffusion cell with an 
exposed surface area of 3.8 cm2. The dialysis membrane 
of the specifications described above was pre-soaked 
(overnight) in phosphate buffer (pH 7.4) before 
using in experiments. On the day of the experiment, 
the membrane was mounted between the donor and 
the receptor compartment of the cell. The receptor 
compartment was filled with PBS (22 mL, pH 7.4), 
magnetically stirred at 200 RPM, and maintained at 
32.0 ± 0.5°C (mimicking human skin temperature). 
Q-MF (containing ~5 mg quercetin) or QPLC-MF 
(containing ~5 mg quercetin) was then placed over the 
membrane. At regular intervals, aliquots (1 mL) of the 
dissolution medium were removed, diluted suitably 
with PBS (pH 7.4), and spectral absorbance recorded 
at 381.2 nm. The measured absorbance was used to 
estimate the cumulative amount of quercetin diffused 
across the membrane.
Ex vivo skin permeation studies
The comparative permeation efficiencies of quercetin 
from the quercetin-loaded matrix films (Q-MF) and 
quercetin present in the prepared QPLC-loaded 
matrix film (QPLC-MF) were determined using a 
method reported previously by Parhi et. al. (32). The 
Franz diffusion cell described above was used for the 
experiments. On the day of experiment, a freshly 
excised, hairless rat abdominal skin membrane was 
prepared and hydrated in PBS (pH 7.4) for 1 hour. 
The skin was mounted between the donor and the 
receptor compartment with the stratum corneum 
facing the donor compartment. Q-MF (containing 
~5 mg quercetin) or QPLC-MF (containing ~5 mg 
quercetin) was then placed on the skin surface (donor 
compartment). The diffusion cell was placed on a 
magnetic stirrer (200 RPM), and the temperature of 
the receptor compartment maintained at 32.0 ± 0.5°C. 
At predetermined intervals, aliquots of samples were 
retrieved from the receptor compartment, diluted and 
assayed at 381.2 nm on a UV-visible spectrophotometer 
(Model: V-630, JASCO International Co., Ltd., 
Tokyo, Japan) to determine the cumulative amount of 
quercetin permeated through the rat skin membrane.
In vivo anti-inflammatory studies
The prepared QPLC-loaded films were subjected to 
preliminary pharmacological evaluation using the 
carrageenan-induced rat paw edema model described 
by Arora et. al. (33). In-house bred Albino rats 
(Wistar strain, 200-250 g) of either sex were used for 
the experiments. The animals were housed in clean 
colony cages maintained at controlled temperature 
(25 ± 5°C) and humidity (50 ± 5% RH) conditions 
with 12-hour light/dark cycle. The food (Pellet chow, 
Brook Bond, Lipton, India) and water was provided ad 
libitum to all animals. The dorsal surface (back) of all 
animals was shaved 12 hours prior to the experiment. 
The Committee for the Purpose of Control and 
Supervision of Experiments on Animals (CPCSEA) 
ethical guidelines were followed when carrying out 
the experimental protocol. The experimental protocol 
(SKBCOP/IAEC/2016 -17, dated August 12, 2016) 
was approved by the Institutional Animal Ethical 
Committee (IAEC) of Smt. Kishoritai Bhoyar College 
of Pharmacy, New Kamptee, Nagpur, Maharashtra, 
India.
The animals were separated into three groups of six 
animals each. The Group I animals received injections 
of a homogenous suspension (0.1 mL, 1% w/v) of 
carrageenan in double-distilled water, in the left hind 
paw, and served as control. Q-MF (20 mg/kg quercetin) 
and QPLC-MF (20 mg/kg quercetin) films were 
applied to the back of group II and group III animals, 
respectively. These animals also received injections of 
carrageenan suspension in the left hind paw, half an 
hour after the treatment with the test formulations. The 
volume of paw edema was measured at 1, 2, 3, 4, 5, 6, 
8, 10, and 12 hours using a digital plethysmometer (VJ 
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InstrumentsTM, Washim, India). The inhibition (%) of 
rat paw edema by the test formulations was calculated 
using Equation 4.
Inhibition edema control edema test drug
edema control
(%) ( ) ( )
( )
=
− x 100 Eq. 4
Statistical analysis
The results are presented as mean ± standard deviation. 
ANOVA followed by post-hoc Dunnett’s or Student’s 
t-test was used to assess the significance of difference 
between groups. The value of p < 0.05 was considered 
to indicate the statistically significant difference 
between groups.
 
RESULTS AND DISCUSSION
Formulation of  quercetin-phospholipid  complex 
(QPLC)
In the current study, a phospholipid-based complex of 
quercetin was prepared by solvent evaporation method 
to improve its aqueous solubility and physiological 
delivery. Several studies have reported the hydrophobic 
nature of flavonoids, resulting in sub-optimal aqueous 
solubility of such compounds (28, 34, 35). These 
studies recommended using dichloromethane, 
tetrahydrofuran or 1, 4-dioxane as a choice of solvent 
for preparing phospholipid-based complexes. However, 
the observations from preliminary studies showed that 
quercetin displayed poor solubility, and precipitated 
out of DCM, THF and 1, 4-dioxane. Hence, 
alternative solvents were explored to overcome this 
challenge. Anhydrous ethanol being  a semi polar, class 
III solvent with low dielectric constant, was chosen as 
solvent of choice for the formulation of QPLC. For the 
preparation of the quercetin- or QPLC-loaded matrix 
films a binary solvent combination of methanol: 
chloroform (1:1) was found to be ideal.
Optimizing variables (central composite design)
The results of the quercetin inclusion efficiency 
obtained from the 20 experimental trial formulations 
suggested by the central composite design are shown in 
Table 2. The prepared trial formulations showed a wide 
range of quercetin inclusion ranging from 65 to 97%. 
The data analyzing software (Design Expert®) displayed 
the results numerically in the form of ANOVA and 
a polynomial equation. For all the trial experiments, 
both quadratic and cubic mathematical models were 
displayed by the design. However, based on the analysis 
of significance, the quadratic model was found to be a 
more reliable description of the results. The obtained 
polynomial, equation (Equation 5), containing the 
magnitude of coefficients, together with the positive 
(+) or negative (-) signs associated with them was used 
to optimize the formulation.
Y X X X X X
X X
= + − + − − −
+
95 31 7 55 6 07 1 78 7 22 4 82
1 73 4 46
1 2 3 1
2
2
2
3
2
. . . . . .
. . 1 2 2 3 1 32 44 1 84X X X X X− −. .
Eq. 5
Where, the coefficients b0, b1, b2, b11, b12, and b22 
exhibited values with p<0.05, indicating their 
significance. Whereas, the coefficients b3, b33, b23, 
and b13 showed p>0.05 indicating that these terms 
were non-significant. The summary statistics of 
the model also showed the correlation coefficient 
(R2 = 0.9908) and F-value (10.08) to be statistically 
significant (p<0.05). The signs (+ or –) associated with 
the coefficients indicated that quercetin inclusion in 
the prepared formulations increased with increasing 
X1 and X3, and decreased with increasing X2. Finally, 
using a numerical optimization method, the levels 
of independent variables used for trial formulation 
number 6 (Table 2) with a desirability value close to 1 
was selected to optimize the formulation. The influence 
of the studied variables on the extent of quercetin 
inclusion is shown in the form of response surface, 
contour and desirability plots in Figure 1.  The levels 
of independent variables for this formulation were 
quercetin: phospholipid at a ratio of 1:1.78, reaction 
temperature at 50°C and reaction time of 2 hours.
Validation of the optimized model
The above model was validated by preparing an 
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Figure 1 The response surface plots, contour plots, and desirability plots of the extent 
of complexation rate (Y, %) as a function of the ratio of quercetin and Phospholipon® 
90H (X1, w:w), and the reaction temperature (X2, °C) and reaction time (X3, h).
additional QPLC formulation using the optimal values 
of the variables. The obtained quercetin inclusion 
(94.8%) in this formulation was comparable to the 
model-predicted value (94.9%). The calculated bias, 
using Equation 6, was found to be 0.12% (< 3%), 
indicating the robustness and validity of the design 
generated model.
Bias predicted value observed value
predicted value
x(%)= − 100 Eq. 6
Physical-chemical characterization of QPLC
Particle size and zeta potential analysis
For sub-micron particles, particle size distribution 
and zeta potential are important indicators of physical 
stability of such particles when dispersed in a liquid 
medium (27, 36). According to the earlier reports, 
APLC formulation with particle size and PDI value 
(107 nm and 0.37, respectively) was found to be 
suitable for oral drug delivery (27). The results of the 
particle size analysis of the prepared QPLC formulation 
are shown in Figure 2 (A). The mean particle size of the 
prepared formulation was observed to be 95.74 ± 1.30 
nm. The polydispersity index of these particles was 
found to be 0.09 ± 0.01 nm, indicating a fairly narrow 
size distribution.
Zeta potential (ζ) measures the distribution of charge 
surrounding the particles, and potentially indicates the 
physical stability of sub-micron particles dispersed in a 
liquid (37). The zeta potential results of the prepared 
QPLC formulation are displayed in Figure 2(B). The 
zeta potential (ζ) for QPLC was – 4.85 ± 0.30 mV, 
indicating fair stability of the colloidal dispersion. 
The particle size, polydispersity index, and the zeta 
potential results indicated that the prepared QPLC 
exhibits relatively stable physical attributes.
Thermal analysis (DSC)
The thermograms obtained from the DSC analysis 
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Figure 2 Particle size distribution (A) and zeta potential (B) of the optimized 
QPLC formulation.
Figure 3 DSC thermograms of (A) pure quercetin, (B) Phospholipon® 90H, (C) the physical mixture (1:1.178) 
of quercetin and Phospholipon® 90H, and (D) QPLC.
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of pure quercetin, Phospholipon® 90H, the physical 
mixture of quercetin and Phospholipon® 90H, and 
the prepared QPLC are shown in Figure 3 (A-D) for 
comparison. As shown in Figure (3A), the thermogram 
of pure quercetin revealed two dissimilar endothermic 
peaks, each at ~130°C and ~318°C. The first peak was 
likely obtained due to the evaporation of water (drying), 
and the second peak can be attributed as the melting 
peak of quercetin. The obtained results were found to 
be consistent with the reports published earlier (38). 
Pure Phospholipon® 90H (Figure 3B) exhibited a series 
of five endothermic peaks at ~84°C, ~105°C, ~120 °C, 
and ~238°C. The first three peaks are related to the 
polar head groups of the phospholipid molecule, and 
the latter two peaks with lower intensities appear to be 
formed due to the transition of phospholipid from its 
gel to a liquid crystal state. These peaks are characteristic 
for Phospholipon® 90H and consistent with those 
reported previously (23, 29). The thermogram of 
the physical mixture (Figure 3C) displayed two 
endothermic peaks i.e., at ~87°C and ~120°C. These 
peaks appeared to be a combination of quercetin and 
Phospholipon® 90 H. The melting peak obtained with 
pure quercetin was absent in this thermogram. It is 
likely that, at increasing temperatures the components 
of the mixture reacted, resulting in the partial formation 
of complex. The thermogram of the prepared QPLC 
(Figure 3D) exhibited a completely new, single broad 
endothermic peak at ~65°C. The original characteristic 
peaks related to pure quercetin or pure Phospholipon® 
90H were absent in this thermogram, indicating the 
formation of a new entity. The findings were consistent 
with published reports in literature (24, 28). These 
observations lead us to conclude that in the prepared 
QPLC, weak intermolecular interactions such as 
hydrogen bonding, and van der Waals interactions 
are established between the phenolic (-OH) groups 
of quercetin and the functional groups of the 
phospholipid molecule, resulting in the formation of 
a stable complex (22, 39, 40).
Fourier transform infrared spectroscopy (FTIR)
The spectra obtained from the FTIR analysis of pure 
quercetin, Phospholipon® 90H, the physical mixture of 
quercetin and Phospholipon® 90H, and the prepared 
QPLC are shown in Figure 4 (A-D). Pure quercetin 
revealed characteristic absorption bands at 3400.65 
cm-1 and 3242.48 cm-1 (related to phenolic O-H 
stretching) (Figure 4A). Other minor absorption bands 
observed for quercetin included the ones at 1665.60 
cm-1 and 1610.63 cm-1 (C=O stretching), 1560.48 
cm-1 and 1521.90 cm-1 (aromatic stretching), and 
1319.37 cm-1 and 1168.91 cm-1 (C-O-C stretching). 
These observations were consistent with those reported 
earlier (19, 21). The Phospholipon® 90H spectrum 
showed strong absorption bands at 2917.46 cm-1 and 
2849.95 cm-1 (C-H stretching associated with the long 
chain fatty acids) (Figure 4B). Other observed peaks for 
the phospholipid molecule were found at 1731.19 cm-1 
(C=O stretching in the fatty ester), 1237.39 cm-1 (P=O 
stretching), 1092.72 cm-1 (P-O-C stretching), and 
970.24 cm-1 (-N+(CH2)3) (41). The physical mixture 
of quercetin and Phospholipon® 90H exhibited 
absorption bands associated with both compounds i.e., 
at 3290.11 cm-1, 2917.29 cm-1, 2849.95 cm-1, 1664.64 
cm-1, 1610.63 cm-1, 1169.88 cm-1, 1240.28 cm-1, 
1092.72 cm-1 and 970.24 cm-1, and consistent with an 
earlier report on this binary mixture (Figure 4C) (42). 
The FTIR spectrum of QPLC is shown in Figure 4D. 
Major absorption bands were observed at 3318.67 cm-
1, 2915.53 cm-1, 1563.37 cm-1, 1166.98 cm-1, 1094.65 
cm-1 and 967.34 cm-1. This spectrum revealed some 
peaks that were unique to QPLC, and some that 
were associated with either the pure components or 
the physical mixture of the components. The peaks 
associated with the pure components or the physical 
mixture was observed to be slightly shifted, possibly 
due to the weak intermolecular interactions between 
the two molecules during the formation of the complex.
Powder x-ray diffractometry (PXRD)
The comparative structural characteristics of pure 
quercetin, Phospholipon® 90H, the physical mixture 
of quercetin and Phospholipon® 90H, and the 
prepared QPLC, as determined by PXRD analysis 
are shown in the form of X-ray diffractograms in the 
Figure 5 (A-D). Figure 5A shows the diffractogram of 
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Figure 4 FTIR spectra of (A) pure quercetin, (B) Phospholipon® 
90H, (C) the physical mixture (1:1.78) of quercetin and 
Phospholipon® 90H, and (D) QPLC. 
Figure 5 The x-ray diffractograms of (A) pure quercetin, (B) 
Phospholipon® 90H, (C) the physical mixture (1:1.78) of quer-
cetin and Phospholipon® 90H, and (D) QPLC.
This Journal is © IPEC-Americas June 2018 J. Excipients and Food Chem. 9 (2) 2018 43
Original Article
Figure 6 1H-NMR spectra of (A) pure quercetin, (B) 
Phospholipon® 90H, and (C) QPLC.
pure quercetin. Quercetin exhibited five sharp peaks 
of high intensity at 11°, 12.5°, 16°, 24°, and 27° 2θ, 
attributable to the crystalline nature of quercetin, and 
have been observed earlier (17). The diffraction pattern 
of pure Phospholipon® 90H revealed a single peak at 
21° 2θ, indicating the partial-amorphous nature of 
the compound (Figure 5B). These observation are 
well supported by reports published earlier (23). The 
physical mixture of quercetin and Phospholipon® 90H 
showed a blend of peaks with varying intensities at 
6°, 11°, 12.5°, 21°, and 27° 2θ (Figure 5C). The low 
intensity peaks were similar to those observed with 
pure quercetin; whereas, the single broad peak can be 
assigned to the phospholipid molecule. The decreased 
intensity of quercetin peaks in the physical mixture 
has been reported to be caused by the lower amount 
of quercetin in mixture, interference by phospholipid 
molecule, in situ formation partial aggregates between 
the components or partial complex formation (23). 
The diffractogram of QPLC, as shown in Figure 
5D, exhibited several closely associated peaks at 11°, 
11.5°, 21°, and 25° 2θ. The pattern and separation 
of peaks in this diffractogram appeared to closely 
match that of pure Phospholipon® 90H. Moreover, 
it is possible that the diffraction peaks observed are 
due to any crystalline components remaining in the 
prepared complex. It is assumed that, in the prepared 
complex, quercetin is molecularly dispersed within 
the phospholipid matrix resulting in a change in the 
crystalline nature of quercetin. Not-surprisingly, the 
intense crystalline peaks of quercetin is thus expected to 
be suppressed, while the diffractogram predominantly 
exhibits characteristic peaks of a partially amorphous 
phospholipid molecule.
Proton nuclear magnetic resonance spectroscopy 
(1H-NMR)
Comparative 1H-NMR spectra of pure quercetin, 
Phospholipon® 90H, and QPLC are shown in Figure 6 
(A, B, and C), respectively. The 1H-NMR spectrum of 
Quercetin in d6-DMSO indicates the presence of five 
phenyl protons across the flavone skeleton. Specifically, 
these appear as doublets at δ 6.19 (H-6; J = 2 Hz), 6.42 
(H-8; J = 2 Hz), 6.88 (H-6’; J = 2 Hz), 7.55 (H-2’; J 
= 2 Hz), 7.68 (H-5’; J = 2 Hz). The chemical shifts of 
three of the four phenolic protons (-OH at C-7, C-3’, 
C-4’) appear as a broad singlet at δ 9.31. The –OH 
proton at C-5 appears at δ 12.47, a downfield shift 
that clearly suggests an intra-molecular hydrogen bond 
with the C-4 oxygen atom. The 1H-NMR spectrum 
of Phospholipon® 90H shows the protons in the alkyl 
region at δ 1.24. When the chemical shifts of these 
two 1H NMR spectra are compared with the 1H-NMR 
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Table 3 Aqueous and non-aqueous solubility of pure quercetin, 
the physical mixture of quercetin with Phospholipon® 90H, and 
the optimized QPLC formulation.
SAMPLES
AQUEOUS 
SOLUBILITY
(µg/mL)
n-OCTANOL 
SOLUBILITY
(µg/mL)
Pure quercetin 2.56 ± 0.45 857.28 ± 0.76
Quercetin: Phospholipon® 90H 
(1:1.78) 31.90 ± 1.12 890.73 ± 0.91
QPLC 58.50 ± 1.02 910.90 ± 1.15
Physical-chemical characterization of QPLC-MF
The results of physical-chemical characterization of 
the prepared QPLC-loaded matrix films are discussed 
below. The average thickness of the prepared films 
was found to be 160.9 ± 11.2 µm. The average weight 
of the films was observed to be 17.02 ± 1.4 mg. The 
folding endurance test results showed that the prepared 
QPLC films survived an average of 230 ± 1.45 strokes 
of folding/unfolding at the same location before 
demonstrating any appearance of racking/breaking. 
These observations are considered to be acceptable 
for similar formulations (30). These results showed 
that when applied on the skin surface the film would 
endure general movements and maintain its integrity. 
The average moisture content (% w/w) of the films 
maintained at controlled temperatures (25°C) was 
found to be 1.24 ± 0.65. This moisture level is not 
expected to influence the physical-chemical stability 
of the formulation. The average maximum moisture 
uptake (% w/w) of the films subjected to higher 
humidity (75% RH) was 8.51 ± 1.08. The increase in 
moisture uptake was possibly due to the presence of 
HPMC E15 as a component of the films, and has been 
reported earlier (30). These films may thus be required 
to be packaged/stored in moisture-free environment. 
The quercetin content of the films was 1.21 ± 0.031 
mg.
Functional characterization of QPLC and QPLC-MF
In vitro dissolution studies
The comparative dissolution profiles of pure quercetin 
and QPLC are shown in Figure 7. The dissolution 
spectrum of QPLC, the following differences emerge: 
(1) The δ 1.24 signal is distinctly lower in terms of 
relative peak height intensity, and (2) the broad singlet 
at δ 9.31 in the QPLC spectrum accounts for only 
two phenolic protons, which suggests that the third 
proton is exchanged with Phospholipon® 90H. All 
other chemical shifts are intact. Thus, the spectral 
comparisons confirm the complexation of quercetin 
with the phospholipid matrix to form the QPLC.
Solubility analysis
The results obtained from the aqueous and non-aqueous 
solubility analysis of pure quercetin, the physical 
mixture of quercetin with Phospholipon® 90H (1:1.78), 
and the optimized QPLC formulation are shown in 
Table 3. The aqueous solubility of pure quercetin 
was found to be ~2.5 μg/mL; whereas, its solubility 
in n-octanol was observed to be ~855 μg/mL. These 
observations are consistent with the fact that quercetin 
is a lipophilic compound. The aqueous solubility of 
quercetin in the physical mixture was found to be ~30 
μg/mL, and significantly (p<0.01) higher than that of 
pure quercetin. This increase (over 10-fold) in aqueous 
solubility of quercetin in the physical mixture could 
be attributed to the close association of amphiphilic 
phospholipid molecules around quercetin. Quercetin 
also exhibited a moderate, albeit non-significant 
increase in n-octanol solubility (~890 μg/mL) in the 
physical mixture. The aqueous solubility of quercetin 
in the prepared QPLC was found to be significantly 
(p<0.001) higher than that of pure quercetin, or 
quercetin in the physical mixture (~57 μg/mL). The 
association of lipophilic quercetin molecules with the 
amphiphilic phospholipid molecules, and possible 
partial amorphization of quercetin could explain 
this dramatic (over 22-fold) increase in the aqueous 
solubility of quercetin in the prepared complex. The 
non-aqueous solubility of quercetin was also found to 
be moderately increased (~910 μg/mL). 
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Figure 7 The in vitro dissolution profiles of pure quercetin and QPLC. Values are mean ± Standard Deviation (n = 3). 
Figure 8 The in vitro diffusion profiles of pure quercetin-loaded matrix films (Q-MF) and QPLC-loaded matrix films 
QPLC-MF. Values are mean ± Standard Deviation (n = 3). 
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rates of pure quercetin and quercetin in QPLC were 
found to be similar during the initial 3 hours, beyond 
which, QPLC exhibited a progressively increasing, 
and a significantly higher rate and extent of quercetin 
dissolution. At the end of 12 hours, pure quercetin 
showed ~69 % dissolution. In the same time period, 
over 90 % quercetin was released from QPLC. The 
observed increase in rate and extent of quercetin from 
QPLC can be attributed to the enhanced wettability 
and solubility of quercetin in the presence of 
amphiphilic phospholipid molecules, and is consistent 
with earlier reports (43). Various release-kinetics 
models such as zero order, first order, Higuchi, and 
Korsmeyer-Peppas, etc. were evaluated to describe 
the release mechanism of quercetin. Upon statistical 
evaluation of the models, Korsmeyer-Peppas model 
was observed to be the best-fitting kinetic model with 
a regression coefficient of R2 = 0.9979 and the release 
exponent n = 0.88. The model describes the dissolution 
as a ‘non-fickian’ release mechanism correlating with 
the diffusion process. This process is known to occur 
in two stages, i.e., dissociation of quercetin molecule 
from QPLC, and diffusion of quercetin molecules 
across the phospholipid matrix (22, 44).
In vitro diffusion studies
Figure 8 shows the comparative in vitro diffusion 
profiles of quercetin from Q-MF and QPLC-MF 
across dialysis membrane. QPLC-loaded films 
exhibited a significantly higher rate and extent of 
quercetin diffusion compared to that observed from 
pure quercetin-loaded films at all tested time points. At 
the end of the 12-hour testing period, only about 60% 
of quercetin was found to diffuse across the membrane 
from Q-MF, compared to over 80% diffusion of 
quercetin observed with QPLC-MF. As seen with the 
dissolution results, we assume that close proximity of 
quercetin to the phospholipid molecules in QPLC-MF 
was likely reason for the higher diffusivity of quercetin 
from these films. In addition, previous studies have 
reported that other film components, i.e., hydrophilic 
polymers, plasticizers, penetration enhancers etc. 
could also potentially influence the diffusion of drug 
through the films (32, 45, 46). Thus, the components 
used to prepare the films in the current study, HPMC 
E15 (hydrophilic matrix forming polymer), dibutyl 
phthalate (plasticizer), and dimethyl sulfoxide 
(penetration enhancer) may have likely contributed to 
quercetin diffusion.
Ex vivo skin permeation studies
A comparison of quercetin permeability across isolated 
rat abdominal skin from Q-MF and QPLC-MF is 
shown in Figure 9. As observed with the diffusion 
results, QPLC-loaded films exhibited a significantly 
higher rate and extent of quercetin permeation 
compared to that observed from pure quercetin-loaded 
films at all tested time points. At the end of the 12-
hour testing period, more than 85 % of the quercetin 
from the QPLC-MF was found to permeate across 
the skin, compared to only about 65% of quercetin 
permeability observed with Q-MF. The differences in 
the permeability profiles of Q-MF and QPLC-MF 
were statistically significant (p<0.01). As described 
above, a combination of phospholipid-complexation 
and permeation-promoting film components can be 
considered as contributing factors to the observed 
enhanced quercetin permeability from QPLC-loaded 
films.
In vivo anti-inflammatory studies
The preliminary pharmacological evaluation of the 
prepared films was conducted using carrageenan-
induced paw edema in Wistar rats to assess the anti-
inflammatory potential of quercetin. The results 
obtained are shown in Figure 10. The group I animals 
subjected to carrageenan-alone treatment showed a 
progressively increasing paw-edema (swelling of the 
paw), exhibited as increasing paw volume over a period 
of 12 hours. The animals receiving Q-MF (group II) or 
QPLC-MF (group III) before carrageenan injections 
showed a significant (p<0.05) protection against 
carrageenan-induced inflammatory swelling. This 
protection was found to be significant over the entire 
observation period of 12 hours. The difference between 
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Figure 9 The ex vivo skin permeation of quercetin from pure quercetin-loaded matrix films (Q-MF) and QPLC-loaded 
matrix films QPLC-MF.  Values are mean ± Stdandard Deviation (n = 3). 
Figure 10 The in vivo anti-inflammatory activity of quercetin-loaded film and QPLC-loaded film on carrageen-
an-induced paw edema in rats. Values are mean ± Stdandard Deviation (n = 6).
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the protective effects of Q-MF and QPLC-MF was not 
statistically significant. However, QPLC-MF appeared 
to be slightly more efficacious than Q-MF. These results 
supports the observations from the in vitro and ex vivo 
results showing increased solubility and permeability 
of quercetin from the prepared QPLC-loaded films. It 
can thus be inferred that phospholipid complexation, 
combined with incorporation of the complex in a 
film formulation enhanced the in vivo bioavailability 
of quercetin, resulting in pharmacological efficacy via 
transdermal route.
CONCLUSIONS
In this current study, a novel combined approach, 
i.e. quercetin-phospholipid complexation and 
incorporation of this complex into a transdermal film 
formulation, to enhance the solubility, permeability, 
and subsequently bioavailability of quercetin is 
presented. The quercetin-phospholipid complex 
(QPLC) was prepared using a solvent evaporation 
method. The formulation and process variables were 
optimized using a central composite design. The 
physical-chemical characterization of the prepared 
formulation supported the formation of a complex, 
and indicated involvement of weak intermolecular 
interactions between quercetin and phospholipid 
molecules. The QPLC-loaded films were prepared 
using a solvent casting method. The physical-chemical 
characterization studies supported the formation of 
acceptable transdermal films. Complexation with 
phospholipid resulted in a significant improvement 
in the solubilization and dissolution rate of quercetin. 
The permeability of quercetin across dialysis membrane 
and excised rat abdominal skin was also found to be 
enhanced in the prepared film formulation. Finally, 
the preliminary pharmacological evaluation of the 
prepared films confirmed the transdermal anti-
inflammatory efficacy of quercetin. The study thus 
provides an alternative approach for efficient delivery of 
phytoconstituents and other pharmacoactive molecules 
with low bioavailability. Further studies are certainly 
warranted to better understand the formulation and 
other functional aspects of the system.
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